NCT06529822 — Washington University School of Medicine neoantigen vaccine trial
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Registry record
| Registry ID | NCT06529822 ↗ |
|---|---|
| Lead sponsor | Washington University School of Medicine |
| Collaborators | Natera, Inc. |
| Phase | Phase 1 |
| Status | Recruiting |
| Indication | Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer |
| Enrollment | 64 participants (target) |
| Start date | 2025-03-20 |
| Primary completion | 2030-01-31 (est.) |
| Last registry update | 17 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06529822), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06529822?
NCT06529822 (Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease) is registered on ClinicalTrials.gov as Phase 1, sponsored by Washington University School of Medicine.
Is NCT06529822 recruiting?
As of the 2026-07-17 registry update, NCT06529822 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06529822?
The lead sponsor is Washington University School of Medicine. Collaborators: Natera, Inc..
What condition does NCT06529822 study?
The registered conditions are Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer. Primary completion is listed as 2030-01-31 (estimated).
Are results available for NCT06529822?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06529822.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.